PFIZER, INC.

(PFE)
  Report
Delayed Nyse  -  04:04 2022-08-05 pm EDT
49.27 USD   -1.18%
02:53aValneva Bets On Lyme Disease Jab As Climate Change Triggers Higher Cases
MT
02:09aClimate change puts Lyme disease in focus for France's Valneva after COVID blow
RE
12:12aMyovant Sciences-Pfizer's Once-daily Endometriosis Drug Obtains US FDA Nod
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Pfizer, BioNTech Sign New $3.2 Billion COVID-19 Vaccine Supply Deal With US

06/29/2022 | 11:07pm EDT


© MT Newswires 2022
Stocks mentioned in the article
ChangeLast1st jan.
BIONTECH SE 1.48% 183.11 Delayed Quote.-28.97%
PFIZER, INC. -1.18% 49.27 Delayed Quote.-16.56%
All news about PFIZER, INC.
02:53aValneva Bets On Lyme Disease Jab As Climate Change Triggers Higher Cases
MT
02:09aClimate change puts Lyme disease in focus for France's Valneva after COVID blow
RE
12:12aMyovant Sciences-Pfizer's Once-daily Endometriosis Drug Obtains US FDA Nod
MT
08/07Pfizer Nears $5 Billion Deal to Purchase Global Blood Therapeutics
MT
08/05Myovant Sciences and Pfizer Receive U.S. FDA Approval of MYFEMBREE®, a Once-Daily Treat..
AQ
08/05Myovant Sciences  and Pfizer Inc. Receive U.S. FDA Approval of MYFEMBREE®, A Once-Daily..
CI
08/05Pfizer In Advanced Talks to Acquire Global Blood Therapeutics for $5 Billion, WSJ Says
MT
08/05Pfizer in advanced talks to buy Global Blood Therapeutics for $5 bln - WSJ
RE
08/05Pfizer in advanced talks to buy Global Blood Therapeutics for $5 billion - WSJ
RE
08/05PFIZER IN ADVANCED TALKS TO BUY GLOB : Dow Jones
MT
More news
Analyst Recommendations on PFIZER, INC.
More recommendations
Financials (USD)
Sales 2022 102 B - -
Net income 2022 34 008 M - -
Net cash 2022 11 522 M - -
P/E ratio 2022 8,63x
Yield 2022 3,29%
Capitalization 276 B 276 B -
EV / Sales 2022 2,61x
EV / Sales 2023 3,30x
Nbr of Employees 79 000
Free-Float 58,9%
Chart PFIZER, INC.
Duration : Period :
Pfizer, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PFIZER, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Last Close Price 49,27 $
Average target price 56,53 $
Spread / Average Target 14,7%
EPS Revisions
Managers and Directors
Albert Bourla Chairman, Chief Executive & Operating Officer
David M. Denton Chief Financial Officer & Executive Vice President
Mikael Dolsten Executive VP, President-Research & Development
Lidia L. Fonseca Executive VP, Chief Digital & Technology Officer
Aida Habtezion Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
PFIZER, INC.-16.56%276 449
JOHNSON & JOHNSON0.02%449 879
ELI LILLY AND COMPANY9.09%286 307
ROCHE HOLDING AG-16.46%271 358
ABBVIE INC.1.95%244 068
NOVO NORDISK A/S2.86%233 797